Endocyte ovarian cancer trial fails and Pfizer wants a deal. I think Synta is safe right now. From a valuation standpoint the price is right. Some may argue high, some may argue low. Downside risk is low, however we have news coming on the HSP90 NSCLC study. May not be great, lower your expectations and listen for guidance. Enchant data in September will either be the rocket or the missle. Spy data also could be surprising to the upside.
that does hurt. What interests me is the chart in March. That jump was from encouraging data from a phase IIb trial that was suddenly reversed. If gaining approval, even temporary, is a lottery then would you buy 1.2 million lottery tickets if they were perceived to be on sale? This is a sign that the any indication of good news for a development in a cancer drug or therapy is going to make some noise.